VCA-894A / Vanda - LARVOL DELTA

Treatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual Patient (clinicaltrials.gov) - P1/2 | N=1 | Active, not recruiting | Sponsor: Vanda Pharmaceuticals | Trial completion date: Mar 2026 ➔ Mar 2027 | Trial primary completion date: Mar 2026 ➔ Mar 2027

Trial completion date • Trial primary completion date • CNS Disorders • Genetic Disorders